Rekah Pharmaceutical Industry
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. Based in Holon.
Rekah Pharmaceutical Industry: net income sharply up (+35.0%), sales up (+2.0%), cash flow sharply up (+401.0%).
- Net income sharply upH1 2026
Net income: ₪−4M, vs. ₪−6M a year earlier, i.e. +35.0%.
- Sales upH1 2026
Revenue: ₪152M, vs. ₪149M a year earlier, i.e. +2.0%.
- Cash flow sharply upH1 2026
Operating cash flow: ₪19M, vs. ₪4M a year earlier, i.e. +401.0%.
- Operating income sharply upH1 2026
Operating income: ₪−1M, vs. ₪−2M a year earlier, i.e. +27.7%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Dividend per share, over 5 years
Total dividends per share paid each calendar year (1 year(s) out of 5 with a payment). Source: Yahoo Finance. The current year is not complete.
Trades by executives and interested parties
2 filing(s) over 12 months · on shares: 0 increase(s) and 0 decrease(s) in holdings.
| Date | Holder | Security | Direction | Quantity | Price | |
|---|---|---|---|---|---|---|
| 23/09/2026 | Dotan Buchsweiler Director | Options | Up | 120,000 | — | Maya › |
| 09/09/2026 | Yuval Bernshtein Executive | Options | Up | 60,000 | — | Maya › |
Filings submitted on Maya (executives, directors, shareholders above 5%). An increase or decrease in holdings may come from a purchase or sale on the exchange, but also from a grant or exercise of options (price "—": grant with no price). Bonds excluded. For details, see the filing on Maya.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 421 | 422 | 424 |
| Current assets | 244 | 217 | 233 |
| Non-current assets | 177 | 206 | 191 |
| Equity | 140 | 156 | 144 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 173 | 138 | 152 |
| Non-current liabilities | 108 | 129 | 128 |
| Revenue | 152 | 149 | 301 |
| Gross profit | 35 | 36 | 70 |
| Operating income | −1 | −2 | −7 |
| Pre-tax income | −3 | −5 | −11 |
| Net income | −4 | −6 | −18 |
| Net income (attributable to shareholders) | −4 | −6 | −18 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | 19 | 4 | 13 |
In millions of shekels. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 23.2% | 24.3% | 23.1% |
| Operating margin | −0.8% | −1.1% | −2.4% |
| Net margin | −2.8% | −4.3% | −6.0% |
| Current ratio (current assets / current liabilities) | 1,4 x | 1,6 x | 1,5 x |
| Equity / total assets | 33.3% | 36.8% | 34.0% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeutic fields, such as urinary tract pain, steroid anti-inflammatories, cough, expectoration and bronchitis, motion sickness, runny nose and congestion, skin disinfection, wounds, burns and insect bites, eye infections, glaucoma, dryness, allergies, fever and pain relief, mouth, depression and anxiety, muscle and joint pain, antibiotics, fungal infections, anemia and nutritional deficits, ear pain, babies and children, etc. The company was founded in 1947 and is based in Holon, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.rekah.co.il
- Maya, Tel Aviv Stock Exchange: company page and reports